Reichard and Klein present clinical and molecular data that stand against removing the cancer descriptor from Gleason score 3 + 3 = 6 prostate cancer. They argue that the evidence of a lack of malignancy is inconclusive and that a change in classification might result in poor patient outcomes.
- Chad A. Reichard
- Eric A. Klein
